Theravance Biopharma Inc

NASDAQ:TBPH   3:59:53 PM EDT
9.46
+0.06 (+0.64%)
Products, Earnings Announcements

Theravance Biopharma Inc QTRLY Loss Per Share $0.11

Published: 08/04/2022 21:34 GMT
Theravance Biopharma Inc (TBPH) - Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update.
Theravance Biopharma Inc - Total Revenue for Q2 of 2022 Was $11.1 Million.
Theravance Biopharma Inc - Total Revenue for Q2 Represents a $1.9 Million Decrease Over Same Period in 2021.
Theravance Biopharma Inc - Cash, Cash Equivalents and Marketable Securities Totaled $132.9 Million As of June 30, 2022.
Theravance Biopharma Inc - Company Expects to Approach Breakeven Cash Flow From Operations in 2h 2022.
Theravance Biopharma Inc - Company Expects Full Year 2022 Research and Development Expense of $45 Million to $55 Million.
Theravance Biopharma Inc Qtrly Loss per Share $0.11.
Revenue is expected to be $11.45 Million
Adjusted EPS is expected to be -$0.05

Next Quarter Revenue Guidance is expected to be $12.3 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.